5-[[4-[2-oxo-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)ethoxy]phenyl]methylene]thiazolidine-2,4-dione

ID: ALA4762532

PubChem CID: 46947466

Max Phase: Preclinical

Molecular Formula: C19H12N2O7S2

Molecular Weight: 444.45

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  O=C1NC(=O)/C(=C/c2ccc(OCC(=O)N3C(=O)c4ccccc4S3(=O)=O)cc2)S1

Standard InChI:  InChI=1S/C19H12N2O7S2/c22-16(21-18(24)13-3-1-2-4-15(13)30(21,26)27)10-28-12-7-5-11(6-8-12)9-14-17(23)20-19(25)29-14/h1-9H,10H2,(H,20,23,25)/b14-9-

Standard InChI Key:  WYOFBYLBNYHOQF-ZROIWOOFSA-N

Molfile:  

 
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
   17.2271  -17.5242    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   17.0166  -18.3166    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   17.8081  -18.1027    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   19.9496  -18.3125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.9485  -19.1361    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.6606  -19.5492    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.3703  -19.1357    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.3675  -18.3089    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.6588  -17.9036    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.0778  -17.8976    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.7911  -18.3035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.8787  -19.1195    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   23.6829  -19.2905    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.0929  -18.5771    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.5396  -17.9678    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.0222  -20.0399    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   23.7060  -17.1636    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   19.2363  -19.5483    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   18.5248  -19.1350    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8126  -19.5472    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.1011  -19.1339    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.8120  -20.3685    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.3488  -19.4688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.1778  -20.2679    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.7997  -18.8560    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2148  -18.1489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.8101  -17.4380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9904  -17.4329    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.5771  -18.1447    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9842  -18.8527    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  4  1  0
  8 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 11  1  0
 13 16  2  0
 15 17  2  0
  5 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 20 22  2  0
 21  2  1  0
  2 26  1  0
 25 23  1  0
 23 21  1  0
 23 24  2  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 25  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4762532

   (5Z)-5-[[4-[2-oxo-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)ethoxy]phenyl]methylidene]-1,3-thiazolidine-2,4-dione

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 444.45

Molecular Weight (Monoisotopic): 444.0086

AlogP: 1.76

#Rotatable Bonds: 4

Polar Surface Area: 126.92

Molecular Species: ACID

HBA: 8

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 6.20

CX Basic pKa: ┄

CX LogP: 1.83

CX LogD: 0.68

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.71

Np Likeness Score: -1.26

References

1. Joshi H,Patil V,Tilekar K,Upadhyay N,Gota V,Ramaa CS.  (2020)  Benzylidene thiazolidinediones: Synthesis, in vitro investigations of antiproliferative mechanisms and in vivo efficacy determination in combination with Imatinib.,  30  (23.0): [PMID:32961322] [10.1016/j.bmcl.2020.127561]

Source

Source(1):

• Scientific Literature